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Abstract
Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many specialist heart failure
practitioners for its effects on systemic and pulmonary hemodynamics and for the relief of symptoms of acute heart failure.
The drug’s impact on mortality in large randomized controlled trials has been inconsistent or inconclusive but, in contrast to
conventional inotropes, there have been no indications of worsened survival and some signals of improved heart failure-related
quality of life. For this reason, levosimendan has been proposed as a safer inodilator option than traditional agents in settings,
such as advanced heart failure. Positive effects of levosimendan on renal function have also been described. At the HEART
FAILURE 2018 congress of the Heart Failure Association of the European Society of Cardiology, safe and effective use
levosimendan in acute and advanced heart failure was examined in a series of expert tutorials. The proceedings of those tutorials
are summarized in this review, with special reference to advanced heart failure and heart failure with concomitant renal dysfunc-
tion. Meta-analysis of clinical trials data is supportive of a renal-protective effect of levosimendan, while physiological obser-
vations suggest that this effect is exerted at least in part via organ-specific effects that may include selective vasodilation of
glomerular afferent arterioles and increased renal blood flow, with no compromise of renal oxygenation. These lines of evidence
require further investigation and their clinical significance needs to be evaluated in specifically designed prospective trials.
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Introduction
The pharmacological effects of levosimendan, an inodilator
indicated for the treatment of decompensated heart failure,
are exerted via three pathways (Fig. 1) [1]: (1) increased
sensitivity of troponin C to calcium in myocardial cells, there-
by inducing a cAMP-independent inotropic effect; (2) open-
ing of adenosine triphosphate-sensitive potassium channels
(KATP channels) in the smooth muscle cells of the vasculature,
so inducing vasodilation; and (3) activation of KATP channels
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in cardiac mitochondria, hence protecting cells against
ischemia/reperfusion injury [1]. As it is a calcium sensitizer
not a calciummobilizer [2, 3], levosimendan does not increase
myocardial oxygen consumption [4, 5], and prevents myocar-
dial apoptosis and remodeling [6, 7].
In its clinical development program, levosimendan showed
beneficial effects on hemodynamic parameters, symptoms,
and neurohormones, with a characteristic prolonged pharma-
cokinetics [8], and an overall positive effect on mortality [9].
Although some pivotal clinical trials failed to show superiority
against comparators in terms of survival [10, 11], other regu-
latory trials [12, 13] as well as the results of the large
ALARM-HF registry [14] showed a favorable impact of
levosimendan on clinical outcomes, versus either placebo or
other inotropes such as dobutamine.
In addition, various lines of clinical investigation have pro-
duced indications of a net beneficial impact of levosimendan
on renal dysfunction [10, 15–20].
At the 2018 congress of the Heart Failure Association of
the European Society of Cardiology (HEART FAILURE
2018, Vienna, Austria, May 27–28), a series of tutorials by
experts from nine European countries (Austria, Belgium,
Denmark, Finland, Germany, Greece, Hungary, Italy, and
Sweden) was delivered examining how to use levosimendan
safely and effectively in acute heart failure (AHF) and ad-
vanced heart failure (AdHF), including an appraisal of its im-
pact in concomitant renal dysfunction. This review summa-
rizes some of those expert perspectives on the optimized use
of levosimendan in these settings.
Levosimendan in the Clinical Literature
Levosimendan’s current indication for the short-term treat-
ment of acutely decompensated severe chronic heart failure
in situations where conventional therapy is not sufficient and
where inotropic support is appropriate rests on experience in
clinical trials from which a series of salient features was
identified.
1. Improved systemic and pulmonary hemodynamics [12,
21, 22] with no significant increase in myocardial oxygen
consumption [23, 24]
2. Relief of symptoms [10–12, 21]
3. A theoretically beneficial effect on neurohormone profile
[10, 11]
4. Prolonged duration of effect due to the formation of an
active metabolite designated OR-1896 [25, 26]
5. Unlike dobutamine, effective also in patients treated with
beta-blockers [12, 27]
The safety profile of levosimendan that emerged from these
studies was largely reassuring [10, 12, 22], with no impair-
ment of diastolic function [28, 29] or development of toler-
ance [26]. Common adverse events associated with
levosimendan use are hypotension, headache, atrial fibrilla-
tion, hypokalemia, and tachycardia [1].
The results of small exploratory clinical trials of
levosimendan in AdHF have been summarized by Nieminen
et al. [30] and were generally affirmative but inevitably of
Fig. 1 mechanisms of action of
levosimendan (data from Papp
et al. [1])
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limited statistical resilience. Two larger studies were subse-
quently performed and reported: the LEVOREP [31], and
LION-HEART [32] clinical trials. As appraised by Pölzl
et al. in a consensus opinion paper [33], those studies support-
ed the view that repetitive i.v. use of levosimendan in AdHF
patients delivered overall benefit in terms of improved hemo-
dynamics, symptom relief, re-hospitalization rates, bio-
markers, and survival but at least one additional suitably-
powered clinical trial in AdHF is desirable to set these con-
clusions on a firm basis of evidence.
Meta-analyses of levosimendan data in various settings,
including AHF and AdHF, indicated a trend towards a surviv-
al benefit that reached statistical significance in some investi-
gations [34–36] though not all [37, 38]. These discrepancies
may have reflected the various selection criteria applied and
the precise natures of the study populations. The larger pooled
analyses were less likely to identify a robust survival gain and
the authors of many of these investigations signaled the need
for more extensive prospectively derived data. Of note, how-
ever, none of these meta-analyses produced any indication that
the use of levosimendan is associated with an increase of
mortality, whereas a worsening impact on survival has been
reported for other inotropes or inodilators [39, 40].
Levosimendan: From Guidelines to Clinical
Practice
The 2016 ESC guidelines on acute and chronic heart failure
assign the same level of evidence and class of recommenda-
tion to all inotropes (Class IIb/Evidence level C) but distin-
guish levosimendan due to its particular mode of action and
recommend its use in cases where there is concomitant use of
beta-blockers [41]. It is not clear how widely that advice is
implemented in real-life clinical practice.
The latest (2018) position statement of the Heart Failure
Association of the European Society of Cardiology on
Advanced Heart Failure (HFA-ESC) on AdHF [42] comments
that BAlthough patients with chronic heart failure have improved
outcomes with implementation of evidence-based therapies, ul-
timately, they still progress to an advanced stage of the disease.^
The authors advise that patients with severe symptoms and re-
duced exercise capacity, or who endure frequent and repeated
hospitalizations, are often refractory to (or cannot tolerate maxi-
mal doses of) established therapies and therefore need something
in addition to standard-of-care medication.
Considered from this perspective levosimendan has attrac-
tive features relevant to AdHF and is distinctly different from
dobutamine and milrinone. Notably, two meta-analyses asso-
ciate repeated use of levosimendan in advanced heart failure
with improved survival [35] and reduced re-hospitalization
[43] (Fig. 2). Given that patients with AdHF may comprise
up to 10% of the overall heart failure population [44–46],
these benefits may be accessible to substantial numbers of
patients. The long duration of action of levosimendan, due
to its OR-1896 metabolite [1, 25, 26], is also relevant in this
context. The position statement of the HFA-ESC [43] further
notes that B…intermittent use of inodilators for long-term
symptomatic improvement or palliation has gained popularity,
especially use of levosimendan, since the hemodynamic effect
may last for >7 days after a 12–24h infusion.^ This may be
considered as a fair summary of practice in this area.
Guidance and expert consensus [30, 47] advise that
levosimendan should ordinarily be administered without a
loading bolus (to minimize risk of hypotension). The contin-
uous 24-h infusion of levosimendan should be administered at
a rate of 0.05–0.1 μg/kg/min. (Some clinicians start
levosimendan infusion at a higher rate, 0.2 μg/kg/min for
the first 60 min in order to reach the desired therapeutic effect
more rapidly, and then reduce the dose to 0.1 μg/kg/min.) It
should be recalled that levosimendan has profound
vasodilatory effects; accordingly, it should be administered
with caution in patients with low blood pressure.
Hypovolemia should be avoided before and during
levosimendan treatment (give fluid as needed; reduce intrave-
nous diuretics when necessary) and measures taken to avoid
hypokalemia (serum/plasma potassium levels should be kept
≥ 4.0 mmol/l during levosimendan infusion).
Heart Failure and Renal Function: a Role
for Levosimendan?
Renal dysfunction is frequently associated with heart failure
and is implicated in worse prognosis [48], and further detri-
ment of QoL [49]. Five types of cardiorenal syndrome (CRS)
with distinct pathophysiologies and clinical presentations
have been described [50].
In patients with heart failure, CRS tends to be encountered
as either Type 1 CRS (worsening of renal function during
treatment for cardiac decompensation) or Type 2 CRS (re-
duced glomerular filtration rate [GFR] [< 60 mL/min/
1.73 m2]): both carry a worse prognosis than heart failure
without attendant renal dysfunction. Multiple mechanisms
contribute to kidney damage in these forms of CRS, including
hypoperfusion, renal venous congestion, interstitial fibrosis,
tubular damage, and nephron loss are linked to neurohormon-
al activation.
The use of inodilators or inotropes may be particularly
beneficial in cases of acute CRS in patients with low blood
pressure or hypoperfusion in the setting of borderline blood
pressure values, and the mechanisms of action of
levosimendan identify it as a plausible option in this setting.
Evidence for a renal-protective action of levosimendan has
been reported from preclinical experiments [51–55]. Improved
renal function becomes evident before any increase in cardiac
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index or left ventricular performancemay be detected, suggest-
ing that any renal-protective effect of levosimendan is exerted
at least in part via organ-specific effects, including pre-
glomerular vasodilation and increased renal artery diameter
and renal blood flow, without compromise of renal oxygena-
tion [56, 57]. An interesting hypothesis has been developed to
E
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Fig. 2 Meta-analyses of the effects of levosimendan on (A) survival (data from Silvetti & Nieminen [35] and (B) re-hospitalization (data from Silvetti
et al. [43]) when used repetitively in advanced heart failure
Fig. 3 Scheme of the putative selective effect of levosimendan on
afferent glomerular arterioles. Levosimendan exerts predominantly a
vasodilation of the afferent arterioles [net effect RBF↑, GFR↑],
while dopamine and dobutamine vasodilate both afferent and
efferent arterioles [net effect RBF↑↑, GFR↔] (from Yilmaz et al.
[51])
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explain those findings: it may be that levosimendan exerts a
selective vasodilation on the afferent arterioles of the renal
glomeruli thus improving renal filtration both directly and in-
directly [51] (Fig. 3).
This finding is consistent with the observation in the
Levosimendan Infusion versus Dobutamine (LIDO) trial
[12], in which levosimendan treatment was associated with
an increase in GFR, whereas treatment with the active
comparator, dobutamine, was not even though it increased
cardiac index and urine output. The explanation of that dis-
parity offered by the LIDO authors is that the capacity of
levosimendan to promote arterial and venous vasodilation
through activation of KATP channels reduces central venous
pressure and thus may be beneficial on GFR in some patients.
Further insights into this matter have been provided in
recently-reported investigations by Lannemyr, Ricksten, and
colleagues in 32 adult patients with chronic heart failure
(mean baseline LVEF ~27%) and impaired renal function
(mean GFR rate < 80 mL/min per 1.73 m2) [58]. As part of
an elective cardiac work-up participants were randomly
assigned to short-term (75 min) treatments with either
levosimendan (loading dose of 12 mcg/kg over 10 min, then
infusion at 0.1 μg/kg/min for 65 mins; n = 16) or dobutamine
(continuous infusion started at 5.0 μg/kg/min for 10 mins then
7.5 μg/kg/min for 65 mins; n = 16).
Both treatments were associated with quantitatively and
qualitatively very similar alterations in systemic hemodynam-
ic indices, including augmentation of cardiac output and car-
diac index, and reductions in systemic vascular resistance in-
dex, central venous pressure, and pulmonary capillary wedge
pressure. Both treatments also significantly enhanced renal
blood flow (levosimendan P < 0.05 vs. baseline; dobutamine
P < 0.001 vs. baseline) but only levosimendan therapy was
associated with a significant increase in GFR (P < 0.05 vs.
baseline: in fact, no alteration in GFR was seen in response
to dobutamine, leading to a significant intergroup difference at
the end of the treatment phase (P = 0.012; Fig. 4). Filtration
fraction was stable during levosimendan treatment but fell in
Fig. 4 Percentage changes in cardiac index (CI), renal blood flow (RBF),
and glomerular filtration rate (GFR) after 75 mins administration of
levosimendan or dobutamine. Derived from Lannemyr et al. [58]. (See
text for further discussion of dosage and results)
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Fig. 5 Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials (data
from Bove et al. [60])
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response to dobutamine (P = 0.045 between groups). The au-
thors of this research conjectured that their data are compatible
with the hypothesis that levosimendan acts as a vasodilator on
afferent renal arterioles, whereas dobutamine dilates both af-
ferent and efferent vessels. They noted also that as both drugs
reduced central venous pressure to a similar extent, this affect
could not be adduced as the cause of the different treatments’
impact on GFR. Of note, the > 20% increase in GFR observed
in patients treatedwith levosimendanwas not accompanied by
renal oxygenation as renal oxygen delivery increased in pro-
portion to the increase in GFR. Lannemyr et al. concede that
theirs is a study of short-term drug exposure in a small patient
cohort: they suggest, nevertheless, that their data question the
assumption that all inotropes that have favorable effects on
central and peripheral hemodynamics can be assumed also
to exert correspondingly favorable effects on renal perfusion
and function, and conjecture that levosimendan "could be the
preferred inotropic agent for treatment of the cardiorenal
syndrome.^
Data on the effects of levosimendan on renal function in
various clinical situations including cardiac surgery [34, 37,
59] and critical illness [60] have been collated in and the
results suggest a renal-protective effect (Fig. 5). Both in these
situations, however, and in heart failure, any such effect re-
quires confirmation in specifically designed prospective trials
of adequate statistical power.
Conclusions
Levosimendan’s current indication for the short-term treat-
ment of acutely decompensated severe chronic heart failure
is based on its unique pharmacological profile as a myocardial
sensitizer and KATP channel activator and from experience
from an extensive clinical trials program.
Renal dysfunction is very common in HF, and a further
worsening of kidney function may be expected during hospi-
talization for AHF. The treatment of cardiorenal syndrome in
decompensated HF is challenging due to variable pathophys-
iology and lack of specifically tailored therapeutic options.
Identifying the underlying processes of kidney dysfunction
is essential to successful management. Volume status should
be checked whenever possible, as well as hypotension and
third space fluid accumulation.
Inotropes may be appropriate for short-term management
of AHF with renal dysfunction; especially, in low-output
states, they may be particularly indicated to avoid renal hypo-
perfusion. Levosimendan, both in the acute setting and in the
repetitive/intermittent context of AdHF, appears to a promis-
ing option to improve renal perfusion or to reverse or amelio-
rate renal dysfunction, but further controlled trials are needed
to confirm the status of levosimendan for this purpose.
The posology of levosimendan in AHF and AdHF is a
central consideration, especially when treating patients with
associated renal dysfunction: dosing of levosimendan should
commence without a bolus, to minimize the risk of hypoten-
sion. A continuous 24-h infusion of levosimendan should be
administered at a rate of 0.05–0.1 μg/kg/min, while maintain-
ing the patient in euvolemic and eukalemic state.
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